SCHEMBL5582071

SCHEMBL5582071

CNc1ncc2c(-c3cccc(Cl)c3)cc(-c3cccc(O)c3)c(OC)c2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 4/20 0.39
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
ADORA1 P30542 6/20 0.38
FBP1 P09467 1/20 0.38
BMPR1A P36894 1/20 0.37
TGFBR1 P36897 1/20 0.37
ACVRL1 P37023 1/20 0.37
ACVR1 Q04771 1/20 0.37
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
MAP4K4 O95819 1/20 0.35
BRAF P15056 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
FABP4 P15090 1/20 0.35
FABP5 Q01469 1/20 0.35
SCN9A Q15858 1/20 0.35
CA12 O43570 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5581770 0.93 ADORA1 (0.40) FYNCSNK2A2CSNK2BCSNK2A1ADORA1
SCHEMBL5581820 0.91 ADORA1 (0.43) CSNK2A2CSNK2BCSNK2A1ADORA1MAP4K4
SCHEMBL5582299 0.89 CSNK2A2 (0.37) FYNCSNK2A2CSNK2BCSNK2A1ADORA1
SCHEMBL5581799 0.89 FYN (0.41) FYNCSNK2A2CSNK2BCSNK2A1ADORA1
SCHEMBL5581729 0.88 FYN (0.52) FYNTGFBR1BRAFJAK2JAK1
SCHEMBL5582247 0.88 ADORA1 (0.39) FYNCSNK2A2CSNK2BCSNK2A1ADORA1
SCHEMBL5581976 0.87 PDE4B (0.39) FYNCSNK2A2CSNK2BCSNK2A1ADORA1
SCHEMBL5582028 0.86 SCN9A (0.40) FYNCSNK2A2CSNK2BCSNK2A1ADORA1
SCHEMBL5581995 0.86 CSNK2A1 (0.50) CSNK2A2CSNK2BCSNK2A1ADORA1MAP4K4
SCHEMBL5582163 0.85 PDE4B (0.42) FYNCSNK2A2CSNK2BCSNK2A1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 FYN 2211/4885CSNK2A2 467/4885CSNK2B 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.